Page last updated: 2024-11-03

proxymetacaine and Myasthenia Gravis

proxymetacaine has been researched along with Myasthenia Gravis in 1 studies

proxymetacaine: RN given refers to parent cpd; structure

Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Meyer, D1
Hamilton, RC1
Gimbel, HV1

Other Studies

1 other study available for proxymetacaine and Myasthenia Gravis

ArticleYear
Myasthenia gravis-like syndrome induced by topical ophthalmic preparations. A case report.
    Journal of clinical neuro-ophthalmology, 1992, Volume: 12, Issue:3

    Topics: Cataract Extraction; Female; Humans; Middle Aged; Myasthenia Gravis; Ophthalmic Solutions; Propoxyca

1992